Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes

Positive

AI Analysis

Summary

Viking Therapeutics announced the closing of concurrent upsized offerings of common stock and convertible senior notes, including full exercise of underwriters' options, raising approximately $575 million in gross proceeds.

Importance:6/10

Sentiment:

0.60

capital_raiseconcurrent_offeringsconvertible_notesmetabolic_disordersendocrine_disorders

Related Companies

$VKTX

Read the original article

Published by PR Newswire Biotech on September 28, 2026 8:30 PM

Read Original